AVXL's logo.
Ticker Symbol: AVXL

Anavex Life Sciences Corporation

$21.75 - 14-07-2024 4 p.m. ET

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0001314052

Company Profile

anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson’s disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 8731
Address: 51 W 52nd St Fl 7th
CEO: Christopher Missling
Tags:
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

Pricing

Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $5.20
Change: -$0.39 ( -6.98%)
Days Range: $5.16 - $5.66
Beta: 1.77
52wk. High: $15.24
52wk. Low: $5.53
Ytd. Change -50.82%
50 Day Moving Average: $6.83
200 Day Moving Average: $8.03
Shares Outstanding: 81951115

Valuation

Market Cap: 42.6B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A